Midatech Pharma (MTP) & Its Peers Head to Head Contrast

Midatech Pharma (NASDAQ: MTP) is one of 526 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its competitors? We will compare Midatech Pharma to related businesses based on the strength of its valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Insider and Institutional Ownership

0.4% of Midatech Pharma shares are owned by institutional investors. Comparatively, 46.8% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 15.0% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Midatech Pharma and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Midatech Pharma 0 0 0 0 N/A
Midatech Pharma Competitors 3729 10924 24908 817 2.56

As a group, “Pharmaceutical preparations” companies have a potential upside of 55.89%. Given Midatech Pharma’s competitors higher possible upside, analysts clearly believe Midatech Pharma has less favorable growth aspects than its competitors.

Risk & Volatility

Midatech Pharma has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Midatech Pharma’s competitors have a beta of 1.17, indicating that their average stock price is 17% more volatile than the S&P 500.

Profitability

This table compares Midatech Pharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Midatech Pharma N/A N/A N/A
Midatech Pharma Competitors -2,667.92% -76.75% -24.48%

Valuation & Earnings

This table compares Midatech Pharma and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Midatech Pharma $9.79 million -$20.70 million -0.57
Midatech Pharma Competitors $2.03 billion $140.19 million -2.19

Midatech Pharma’s competitors have higher revenue and earnings than Midatech Pharma. Midatech Pharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Midatech Pharma Company Profile

Midatech Pharma PLC, a specialty pharmaceutical company, focuses on developing and commercializing products in oncology and immunotherapy in the United States and the United Kingdom. The company operates through two segments, Pipeline Research and Development; and Commercial. Its products include Zuplenz, an oral soluble film for moderately emetogenic chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, and post-operative nausea and vomiting; Gelclair, an oral gel barrier device indicated for the management and relief of pain due to oral mucositis; Oravig, an orally dissolving buccal tablet for oral thrush; and Soltamox, an oral liquid solution of tamoxifen citrate, for the treatment and prevention of breast cancer. Midatech Pharma PLC is collaborating with universities and pharmaceutical companies to develop its platform technologies into a range of products. Midatech Pharma PLC was founded in 2000 and is headquartered in Abingdon, the United Kingdom.

Receive News & Ratings for Midatech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Midatech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply